Full Text
PCN312 - HOW HAS THE RELAUNCHED CANCER DRUGS FUND AFFECTED NICE’S APPROVAL OF NOVEL ONCOLOGY TECHNOLOGIES?

Abstract

Authors

N. Illingworth C. Shaw J.R. Crutwell R. Miller D. Fountain

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×